Office Hours:
Mon thru Thur 8:30 to 4:00pm
Fri 8:30 to 12:00pm

Phone: 623-878-2100

Address:
6677 W. Thunderbird Rd. Suite I - 164
Glendale, AZ 85306

 

Follow us on:

• 

Neurostar® Effectiveness

Clinical trials have demonstrated the effectiveness of NeuroStar® TMS Therapy in treating patients who have not benefited from prior antidepressant medication. NeuroStar® TMS Therapy has the largest clinically studied data set of any TMS Treatment program, including over 900 participants. Clinical trials have shown that NeuroStar® may help to reduce or diminish symptoms of depression after 4 to 6 weeks of treatment.

The NeuroStar® Advanced Therapy’s Depression Outcomes Registry now has over 10,000 patient outcomes across 116 clinical practice sites, making it the largest outcomes registry in the world for Major Depressive Disorder (MDD). The registry’s latest findings showed that 73 percent of patients treated with NeuroStar experienced significant depression symptom improvement and 52 percent of patients achieved remission.

An Effective and Durable Option for Treating Major Depressive Disorder

In an independent, randomized, controlled trial funded by the National Institute of Mental Health, patients treated with NeuroStar® TMS Therapy were four times more likely to feel their depression symptoms significantly improve, compared to a control group of patients. ¹

When studied over the course of a year:

• 1 in 2 TMS patients experienced significant improvement in their depression symptoms
• 1 in 3 experienced complete remission from their depression symptoms.²

Patients treated with the NeuroStar® TMS System also experienced significant improvement in anxiety and physical symptoms (such as appetite changes, aches and pains, and lack of energy) associated with depression.

 

 

 

 

 

 

 

 

NeuroStar TMS is the only TMS system with the durability of its effects estimated to last 12 or more months. After the end of a 4 to 6 week treatment period, only 1 in 3 NeuroStar® patients needed to come back for maintenance TMS sessions, or 'reintroduction' during this 12-month period. ³

NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment.

View TMS Therapy safety data

References:

1. Janicak PG, et al. (2010). Durability of Clinical Benefit with Transcranial Magnetic Stimulation (TMS) in the Treatment of Pharmacoresistant Major Depression: Assessment of Relapse During a 6-Month, Multisite, Open-Label Study. Brain Stimulation. 3(4):187-199. www.ncbi.nlm.nih.gov/pubmed/20965447
2. Dunner DL, et al. (2014). A Multisite, Naturalistic, Observational Study of Transcranial Magnetic Stimulation (TMS) for Patients with Pharmacoresistant Major Depressive Disorder: Durability of Benefit Over a 1-Year Follow-Up Period. J Clin Psychiatry. 75(12):1394-1401. www.ncbi.nlm.nih.gov/pubmed/25271871
3. Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 29(7):587-96. https://doi.org/10.1002/da.21969
4. Sackeim HA, et al. (2020). Clinical outcomes in a large registry of patients with major depressive disorder treated with Transcranial Magnetic Stimulation. Journal of Affective Disorders. 277:65-74. https://doi.org/10.1016/j.jad.2020.08.005